Cancer is a significant worldwide public health issue. The adverse effects of anticancer chemotherapies still compromise the quality of life of patients. To identify new potential targeted anticancer agents, a series of pyrazoline derivatives were synthesized and evaluated for anticancer effects on A549 (human lung adenocarcenoma cell line). In silico evaluation methods were done before synthesis through molecular docking via genetic optimization for ligand docking (GOLD) Suite software with EGFR tyrosine kinase and exhibited significant tyrosine kinase inhibition activities compared with Erlotinb as a reference drug due to their hydrogen bonding and short contact interaction with key amino acids and these results are compatible with the experimental findings. The new derivatives were synthesized by incorporating pyrazoline pharmacophore into nabumetone moiety as a starting molecule and the chalcone derivatives as intermediate products. The compounds structure were confirmed by 1 H-NMR, some physicochemical properties and infrared spectroscopy. An in vitro assay demonstrated that the final compounds (P1, P2, P3 and P4) exerted potent to moderate cytotoxic activity in the micromolar range with an IC50 values (15.409µM, 7.24µM, 27.05µM, 22.45µM) respectively when compared with Erlotinib (IC50 =25.23µM) while (P5&P6) show weak activity. Pharmacokinetic and physicochemical properties of the final compounds predicted by using ADME evaluations. The results showed all the synthesized compounds have high oral bioavailability and good GI absorption.